%0 Journal Article
%T The Impact of miRNA-155 Expression on Treatment Outcome in Adult Acute Myeloid Leukemia Patients
%A Tarek Elgohary
%A Fouad Abu-Taleb
%A Rania Ghonaim
%J Journal of Cancer Therapy
%P 203-214
%@ 2151-1942
%D 2019
%I Scientific Research Publishing
%R 10.4236/jct.2019.103017
%X <strong>Background: </strong><span>Acute myeloid leukemia
is a heterogeneous hematologic malignancy associated with gene mutations,
chromosomal rearrangements, deregulation of gene expression and epigenetic
modifications.</span><span \"=\"\"> </span><span>The</span><span \"=\"\"> </span><span>treatment outcome of</span><span \"=\"\"> </span><span>AML</span><span \"=\"\"> </span><span \"=\"\"><span>is highly variable
signifying the heterogeneous nature of the disease. </span><b><span>Aim of the Study: </span></b></span><span \"=\"\"><span>To</span><b> </b></span><span>evaluat</span><span>e</span><span \"=\"\"><span> miRNA-155 expression
level as a prognostic marker for adult patients with acute myeloid leukemia. </span><b><span>Patients
and Methods: </span></b><span>101 subjects were included in this study. They were classified
into 2 groups, patient group (61 adult patients with newly diagnosed acute
myeloid leukemia) and control group (40 apparently healthy adult subjects).</span></span><span \"=\"\"> </span><span>miRNA-155 expression
was assessed using real time PCR using QIAGEN, miScript, Quanti</span><span \"=\"\"> </span><span>Tect</span><span> and</span><span> Rotor-isc (QIAGEN
Group) PAXgene (pre Analytix</span><span \"=\"\"> </span><span \"=\"\"><span>Gmbh). Samples were either peripheral blood or bone
marrow aspiration sample. </span><b><span>Results</span></b><span>: Roc curve detect</span></span><span>ed</span><span \"=\"\"><span> 2.85 as best fit
value of miRNA-155 for discriminating patients from healthy controls with
sensitivity 92.3%, specificity 88.5%, AUC 0.98 and CI (0.96 - 0.99) (p &lt; 0.001).
The 75</span><sup><span>th</span></sup></span><span \"=\"\"> </span><span>percentile value of the patient group </span><span>was </span><span>taken as prognostic cut off value with a value &lt;
9.8 as low miRNA-155 and a value ¡Ý 9.8 as high miRNA-155.</span><span \"=\"\"> </span><span>The expression level
of miRNA-155 was significantly higher in AML patients than in controls (p =
0.002). Patients with high miRNA expression had a signi</span><span>fi</span><span>cantly higher white blood cells count (p = 0.002),
bone marrow blasts (p = 0.006) and peripheral blood blasts (p = 0.006) compared
to patients with low miRNA-155 expression.</span><span \"=\"\"> </span><span>Patients with poor cytogentics had a significantly
higher level of miRNA-155 expression compared to patients with favorable
cytogentics (p = 0.007). The complete remission rate was significantly higher
in patients with low miRNA-155 expression compared to those with high
expression
%K miR-155
%K Micro-RNA
%K AML
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=90873